FDA committee recommends GSK shingles vaccine

07:46 14/09/2017
StockMarketWire.com - GlaxoSmithKline has announced that the US Food and Drug Administration's vaccines and related biological products advisory committee has voted unanimously that the data support the efficacy and safety of Shingrix for the prevention of herpes zoster (shingles) in adults aged 50 and over.

FDA advisory committees provide non-binding recommendations for consideration by the FDA, with the final decision on approval made by the FDA.

GSK senior vice-president and head of vaccines R&D, Dr. Emmanuel Hanon, said: "Shingles is a painful and potentially serious condition.

"The risk of developing shingles increases with age and it is estimated that up to one in three people in the United States will develop shingles.

"Today's vote brings us one step closer to approval of Shingrix, which is specifically designed to overcome age-related weakening of the immune system."



Story provided by StockMarketWire.com

Forex

Commodities

What the Papers Say

telegraph financial times daily mail daily express independent times
20:52 German election 2017 polls and odds...
source: The Telegraph
20:30 People injured in 'suspected gas...
source: The Telegraph
20:02 People injured in 'suspected gas...
source: The Telegraph
20:00 Agony goes on for family of missing RAF...
source: The Telegraph
19:51 Score of...
source: The Telegraph
19:39 Prince Harry meets Melania Trump ahead of...
source: The Telegraph
19:22 US bombers fly close to North Korean...
source: The Telegraph
19:17 Nibiru: How the nonsense Planet X...
source: The Telegraph
19:15 German election 2017 polls and odds...
source: The Telegraph
19:14 Fizzy milk could be about to hit...
source: The Telegraph
[more ...]